Scientific Programme

The course will provide a comprehensive update on the treatment of thoracic malignancies with special emphasis on the multimodality treatment. To that regard there is a wide participation of thoracic surgeons, chest physicians and oncologists.

At the end of the course participants will be able to:

– have a deeper knowledge of diagnostic modalities for thoracic malignancies

– be familiar with the most up to date form of treatment according to stage

– be able to choose and offer the patient several therapeutic modalities with an explanation of advantages and disadvantages

– be confident in drawing a treatment plan involving several specialists and treatment modalities (surgery, oncology and radiotherapy).

November 6, 2020

  • 8:30
    8:45

    Registration

  • 8:45
    9:00

    Introduction

I° SESSION

How do we diagnose lung cancer?

CHAIR: A.Brunelli, M.Torre

  • 9:00
    9:20

    Nelson study: what have we learnt and what is left to do?

    T. D’amico

  • 9:20
    9:40

    Alternatives to CT screening: are they viable?

    G.Massard

  • 9:40
    10:00

    New bronchoscopic techniques: friend or foe?

    N. Navani

  • 10:00
    10:20

    Radiologic diagnosis of lung cancer: when is it enough?

    A. Patterson

  • 10:20
    10:40

    Intraoperative radiologic biopsy: does the cost justify the result?

    K.Papagiannopoulos

  • 10:40
    11:00

    Questions

  • 11:00
    11:30

    Coffee Break

II° SESSION

How to approach lung cancer   

Chair: G.Cardillo, K.Papagiannopoulos

  • 11:30
    11:50

    GGOs and subsolid lesions: classification and natural history

    N. Novoa

  • 11:50
    12:10

    Resection vs surveillance for GGOs

    N. Navani

  • 12:10
    12:30

    Surgery vs SBRT for operable patients: is there a role?

    S. Arcangeli

  • 12:30
    12:50

    Surgery vs SBRT for operable patients: is there a role?

    S. Arcangeli

  • 12:50
    13:10

    Surgery vs ENB navigation ablation

    K. Lau

  • 13:10
    13:30

    Question

  • 13:30
    14:30

    Lunch

III° SESSION

Preoperative management

Chair: T.D’Amico, P.Solli

  • 14:30
    14:50

    Do we need to stage the mediastinum?

    E. Ruffini

  • 14:50
    15:10

    Do we need to biopsy a lesion before surgery?

    M. Ismail

  • 15:10
    15:30

    Neoadjuvant treatments for early stage lung cancer: is there a role?

    D. Cortinovis

  • 15:30
    15:50

    Where do we draw the line for indications for surgery? The truly inoperable patient

    A. Brunelli

  • 15:50
    16:10

    Question

  • 16:10
    16:40

    Coffee Break

IV° SESSION

How to treat early stage lung cancer    

Chair: R.Crisci, G.Massard

  • 16:40
    17:00

    Robotic surgery

    D. G. Rivas

  • 17:00
    17:20

    Minimally invasive approacches

    D. G. Rivas

  • 17:20
    17:40

    Hybrid techniques

    P. M. Falcoz

  • 17:40
    18:00

    How much can we push minimally invasive surgery?

    H. Batirel

  • 18:10
    18:20

    Question and Closing Remarks

  • 18:20

    End of Day 1

November 7, 2020

  • 8:00
    8:30

    Registration

V° SESSION

Medical treatments      

Chair: S.Arcangeli, N.Navani, J.Remon

  • 8:30
    8:50

    Immunotherapy in resectable NSCLC

    Y. Summers

  • 8:50
    9:10

    News in immunotherapy world in advanced NSCLC: improving the bar

    N. Peled

  • 9:10
    9:30

    Neoadjuvant strategies in oncogene addicted tumors: is it now the time?

    I. Gil-Bazo

  • 9:30
    9:50

    Oncogene addicted tumors: new OMA’s to know

    C. Rolfo

  • 9:50
    10:10

    SCLC a new dawn or the same old refrain

    D. Cortinovis

  • 10:10
    10:30

    Questions

  • 10:30
    11:00

    Coffee Break

VI° SESSION

Multimodality treatments         

Chair: M.Nosotti, A.Patterson

  • 11:00
    11:30

    Concomitant neoadjuvant chemoRT vs neoadjuvant chemo vs surgery upfront

    T. D’amico

  • 11:30
    12:00

    Treatment of (un)resectable stage III lung cancer

    F. Cappuzzo

  • 12:00
    12:30

    Oligometastatic disease: when is too much for surgery?

    G. Rocco

  • 12:30
    13:00

    Multimodality approach for orphan diseases: MPM and SCLC

    J. Remon

  • 13:00
    13:30

    CME Tests

  • 13:30

    Symposium End

  • 13:30
    14:30

    Lunch

6/7 NOVEMBER 2020 – MILANO

The multidisciplinary treatment of lung cancer